Evidence map›Paper›PMID 42684960›Full record

ArticleMicrobiology spectrum2026

A comparative analysis of performance and time-to-result for VITEK REVEAL versus MicroScan during antimicrobial susceptibility testing for gram-negative bacteremia.

Melissa Gitman, Albert Chow, Cecilia Hernandez, Manohar Mutnal, Noah Henry, Katelyn Teckenbrock, Shikha Chaudhary, Paul D Fey, John S Stevenson, Yolande A Chan and 12 more

Abstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Melissa GitmanIcahn School of Medicine at Mount Sinai and Mount Sinai Health System, New York, New York, USA.ORCID 0000-0002-6960-0763
Albert ChowMount Sinai Health System, New York, New York, USA.
Cecilia HernandezMount Sinai Health System, New York, New York, USA.
Manohar MutnalBaylor Scott and White MC Temple, Temple, Texas, USA.ORCID 0000-0002-0452-7382
Noah HenryBaylor Scott and White MC Temple, Temple, Texas, USA.
Katelyn TeckenbrockBaylor Scott and White MC Temple, Temple, Texas, USA.
Shikha ChaudharyBaylor Scott and White MC Temple, Temple, Texas, USA.
Paul D FeyUniversity of Nebraska Medical Center, Omaha, Nebraska, USA.ORCID 0000-0003-0939-6884
John S StevensonUniversity of Nebraska Medical Center, Omaha, Nebraska, USA.ORCID 0009-0005-5631-5794
Yolande A ChanUniversity of Nebraska Medical Center, Omaha, Nebraska, USA.
Alexander D PydenLahey Hospital and Medical Center, Burlington, Massachusetts, USA.
Matthew KearneyLahey Hospital and Medical Center, Burlington, Massachusetts, USA.
Benjamin von BredowCorewell Health, Royal Oak, Michigan, USA.ORCID 0000-0001-8924-2193
Amer Ait ChebibCorewell Health, Royal Oak, Michigan, USA.
Elizabeth M GarrettPenn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.ORCID 0009-0004-4066-8029
Meng PuPenn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.
Shivaramu KeelarabioMerieux, Inc., Durham, North Carolina, USA.
Richard RemingtonbioMerieux, Inc., Durham, North Carolina, USA.
Cecilia CarvalhaesbioMerieux, Inc., Durham, North Carolina, USA.
Carrie LaskybioMerieux, Inc., Durham, North Carolina, USA.
Theresa Okeyo OwuorbioMerieux, Inc., Durham, North Carolina, USA.
April M BobenchikPenn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.ORCID 0009-0008-6167-198X

Funding

bioMerieux, Inc.
6 · The paper itself

Abstract

Fast and reliable antimicrobial susceptibility testing (AST) is essential for timely optimization of therapy in patients with bloodstream infections. This multicenter study assessed the performance of the bioMérieux VITEK REVEAL (VITEK REVEAL) system in comparison with the Beckman Coulter MicroScan (MicroScan) using positive blood culture (PBC) isolates. A total of 553 gram-negative PBCs were obtained from six clinical sites, with Enterobacterales representing the majority (91.1%, 504/553). Overall, 7,945 antimicrobial/organism combinations were evaluated to compare AST performance between VITEK REVEAL and MicroScan. VITEK REVEAL demonstrated strong concordance with MicroScan, achieving 98.1% essential agreement (EA) and 96.0% categorical agreement (CA). High agreement rates were observed for most antimicrobials, including amikacin, ceftazidime-avibactam, and meropenem-vaborbactam, each showing 100% EA and CA. Across all evaluations, discrepancies included 38 very major discrepancies (VMDs), 64 major discrepancies (MDs), and 218 minor discrepancies. Reference broth microdilution discrepant testing resolved most VMDs in favor of VITEK REVEAL, whereas most MDs aligned with MicroScan results. Species-level performance demonstrated strong agreement:

Indexed as

Anti-Bacterial AgentsBacteremiaGram-Negative BacteriaGram-Negative Bacterial InfectionsHumansMicrobial Sensitivity TestsTime FactorsAnti-Bacterial Agentsautomated susceptibility testingblood culturesEnterobacteralesfast antimicrobial susceptibility testinggram-negative bacilligram-negative bacteriaminimum inhibitory concentrationtime to result

Identifiers

PMID42684960
PMCPMC13689412

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.